| ORIGINAL ARTICLE |
|
| Year : 2017 | Volume
: 2
| Issue : 2 | Page : 68-72 |
|
|
Safety of continuing warfarin therapy in patients undergoing cardiac resynchronization therapy device implantation
Chad M House1, Robert Gao2, Imdad Ahmed3, William B Nelson3, Dennis W.X. Zhu3
1 Department of Cardiology, Regions Hospital, St. Paul, Minnesota; Health Partners Medical Group, Minneapolis, USA
2 University of Minnesota Medical School, Minneapolis, Minnesota, USA
3 Department of Cardiology, Regions Hospital, St. Paul, Minnesota; Health Partners Medical Group, Minneapolis; University of Minnesota Medical School, Minneapolis, Minnesota, USA
Correspondence Address:
Dr. Dennis W.X. Zhu
Mail Stop 11102M, 640 Jackson Street, St. Paul, MN 55101
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/IJHR.IJHR_5_17
|
|
|
Background: Continuing warfarin therapy is considered safe for patient undergoing pacemaker or implantable cardioverter defibrillator procedures, but less evidence exists for patients undergoing cardiac resynchronization therapy (CRT) device implantation. Subjects and Methods: We retrospectively evaluated 136 consecutive patients who received a CRT device. Three periprocedural anticoagulation strategies were utilized: Group 1, continuation of therapeutic warfarin; Group 2, cessation of warfarin with heparin bridging; and Group 3, cessation of anticoagulation temporarily. Groups were compared on the incidence of complications. Results: Of the 136 patients, 87 (64%) were in Group 1, 18 (13%) were in Group 2, and 31 (23%) were in Group 3. Group 1 patients had an international normalized ratio of 2.3 ± 0.5, which was significantly higher than the other two groups. Coronary sinus dissection occurred in four patients: Three in Group 1 and one in Group 2, but no patient experienced pericardial effusion or tamponade. Group 2 experienced a higher incidence of pocket hematoma (P = 0.0065) and a longer length of hospital stay (P = 0.0069) than Group 1. Transient ischemic attack occurred in one patient in Group 3. Conclusion: Continuing warfarin with therapeutic international normalized ratio seems to be safe in individuals undergoing CRT device implantation.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
